Commentary|Podcasts|November 20, 2025

Pharma Pulse: Regulatory Crucible, China Supply Risk, and Texting Triumphs in Diabetes Care

In today’s Pharma Pulse, we dissect the resource drain of new pilot programs, the growing concerns over global supply chain dependency, and the simple tech intervention improving glycemic control.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

  • First up, the regulatory landscape. An article published in PharmTech highlights the significant strain caused by emerging pilot programs, such as the CNPV framework. While aiming for better oversight, this initiative creates a regulatory "crucible" that demands substantial resources. For many companies, the internal resource drain and hidden trade-offs involved in compliance are proving to be a major obstacle to innovation and efficiency. The industry must balance these regulatory ambitions with the practical capacity of drug manufacturers.
  • Switching gears to global security, a new report cautions that the dominance of China in the pharmaceutical sector is posing growing risks to the US drug supply chain. The concentration of drug ingredients and manufacturing capacity overseas makes the US vulnerable to geopolitical instability and supply shocks. Experts are urging policymakers and industry leaders to prioritize strategies that diversify sourcing and bolster domestic manufacturing to ensure a resilient and secure supply of essential medicines for the American public.
  • Lastly, a positive note on patient care. New research is showing the profound impact of simple text-messaging interventions on individuals managing diabetes. These targeted, timely texts are helping patients better adhere to their treatment plans and are successfully leading to improved glycemic control. This highlights how accessible, low-cost digital tools can bridge communication gaps, foster better habits, and significantly enhance outcomes for chronic disease management.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.
CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.